2种Rho相关卷曲螺旋形成蛋白激酶对经皮冠状动脉介入治疗无复流的预测价值

Predictive value of two Rho-associated coiled-coil containing kinase for no reflow by percutaneous coronary intervention

  • 摘要: 目的 探讨Rho相关卷曲螺旋形成蛋白激酶(ROCK)1和ROCK2对急性ST段抬高型心肌梗死(STEMI)患者经皮冠状动脉介入治疗(PCI)无复流的预测价值。方法 选取168例接受PCI的STEMI患者作为研究对象,根据是否发生无复流分为无复流组和血流正常组,并分别根据ROCK1、ROCK2表达情况分为高表达组和低表达组。使用酶联免疫吸附试剂盒检测患者血清ROCK1、ROCK2水平,分析无复流组与血流正常组的血清ROCK1、ROCK2水平差异,分析STEMI患者PCI无复流的危险因素,并分析ROCK1、ROCK2对STEMI患者PCI无复流的预测价值。结果 168例STEMI患者中,46例发生无复流,发生率为27.38%。无复流组的Killip分级、发病至入院时间、未使用预防性无复流药物者占比、血清ROCK1水平、血清ROCK2水平高于或长于血流正常组,差异有统计学意义(P<0.05)。ROCK1高表达组的无复流发生率高于ROCK1低表达组,ROCK2高表达组的无复流发生率高于ROCK2低表达组,差异有统计学意义(P<0.05)。多因素Logsitic回归分析显示,Killip分级为Ⅲ~Ⅳ级、发病至入院时间较长、未使用预防性无复流药物、血清ROCK1水平较高、血清ROCK2水平较高均为STEMI患者PCI无复流的独立危险因素(P<0.05)。受试者工作特征曲线显示,ROCK1、ROCK2对STEMI患者PCI无复流的预测价值较高,且两者联用后预测价值提升,曲线下面积为0.789(95%CI:0.711~0.867)。结论 血清ROCK1、ROCK2水平较高是STEMI患者PCI无复流的危险因素,两者联合检测对PCI无复流具有较高的预测价值。

     

    Abstract: Objective To investigate the predictive value of Rho-associated coiled-coil containing kinase1 (ROCK1) and ROCK2 for no reflow in patients with acute ST segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI). Methods A total of 168 STEMI patients who received PCI were selected as study objects, and were divided into no reflow group and normal blood flow group based on whether no reflow occurred, were divided into high expression group and low expression group based on the expression of ROCK1 and ROCK2. Enzyme linked immunosorbent assay was used to detect the levels of serum ROCK1 and ROCK2. The differences in serum levels of ROCK1 and ROCK2 between the no reflow group and the normal blood flow group were analyzed, and the risk factors for no reflow in STEMI patients undergoing PCI treatment were analyzed, the predictive value of ROCK1 and ROCK2 for no reflow in STEMI patients undergoing PCI treatment were analyzed. Results Of 168 STEMI patients, no reflow occurred in 46 cases (27.38%). The Killip grade, time from onset to hospital admission, proportion of patients who did not use prophylactic no reflow, serum ROCK1 level and serum ROCK2 level in the no reflow group were higher or longer than those in the normal blood flow group (P<0.05). The incidence of no reflow in ROCK1 high expression group was higher than that in ROCK1 low expression group, and the incidence of no reflow in ROCK2 high expression group was higher than that in ROCK2 low expression group, the differences were statistically significant (P<0.05). The incidence rates of no reflow in the ROCK1 high expression group and ROCK2 high expression group were higher than that in the ROCK1 low expression group and ROCK2 low expression group (P<0.05). Multiple Logistic regression analysis showed that Killip grade of III to IV, longer onset to admission time, no using prophylactic no reflow drugs, and higher serum levels of ROCK1 and ROCK2 were all risk factors for no reflow in STEMI patients undergoing PCI (P<0.05). Receiver operating characteristic curve showed that ROCK1 and ROCK2 had high predictive value for PCI in STEMI patients without reflow, and the predictive value was increased after the combination of ROCK1 and ROCK2. The area under the curve was 0.789(95%CI, 0.711 to 0.867). Conclusion High serum levels of ROCK1 and ROCK2 are both risk factors for no reflow in STEMI patients undergoing PCI, and their combination has high predictive value for no reflow.

     

/

返回文章
返回